Evommune, Inc. (EVMN)
20.70
+0.21
(+1.02%)
USD |
NYSE |
Jun 11, 16:00
20.70
0.00 (0.00%)
After-Hours: 18:31
Evommune Enterprise Value : 535.67M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 535.67M |
| June 09, 2026 | 535.67M |
| June 08, 2026 | 524.86M |
| June 05, 2026 | 515.14M |
| June 04, 2026 | 542.87M |
| June 03, 2026 | 508.29M |
| June 02, 2026 | 511.53M |
| June 01, 2026 | 596.18M |
| May 29, 2026 | 634.36M |
| May 28, 2026 | 637.96M |
| May 27, 2026 | 638.32M |
| May 26, 2026 | 638.68M |
| May 22, 2026 | 621.39M |
| May 21, 2026 | 645.88M |
| May 20, 2026 | 600.14M |
| May 19, 2026 | 558.36M |
| May 18, 2026 | 586.09M |
| May 15, 2026 | 623.19M |
| May 14, 2026 | 615.99M |
| May 13, 2026 | 636.52M |
| May 12, 2026 | 614.91M |
| May 11, 2026 | 633.64M |
| May 08, 2026 | 623.19M |
| May 07, 2026 | 608.06M |
| May 06, 2026 | 655.97M |
| Date | Value |
|---|---|
| May 05, 2026 | 667.85M |
| May 04, 2026 | 648.76M |
| May 01, 2026 | 680.10M |
| April 30, 2026 | 654.89M |
| April 29, 2026 | 656.69M |
| April 28, 2026 | 719.00M |
| April 27, 2026 | 698.11M |
| April 24, 2026 | 711.80M |
| April 23, 2026 | 728.37M |
| April 22, 2026 | 774.47M |
| April 21, 2026 | 808.69M |
| April 20, 2026 | 805.08M |
| April 17, 2026 | 786.36M |
| April 16, 2026 | 761.86M |
| April 15, 2026 | 767.99M |
| April 14, 2026 | 756.82M |
| April 13, 2026 | 770.51M |
| April 10, 2026 | 716.48M |
| April 09, 2026 | 829.58M |
| April 08, 2026 | 774.83M |
| April 07, 2026 | 690.55M |
| April 06, 2026 | 682.98M |
| April 02, 2026 | 652.01M |
| April 01, 2026 | 605.18M |
| March 31, 2026 | 625.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Apogee Therapeutics, Inc. | 5.142B |
| Kymera Therapeutics, Inc. | 5.859B |
| Mineralys Therapeutics, Inc. | 1.313B |
| GRAIL, Inc. | 1.638B |
| MapLight Therapeutics, Inc. | 952.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.67M |
| Total Expenses (Quarterly) | 21.67M |
| EPS Diluted (Quarterly) | -0.6437 |
| Earnings Yield | -11.53% |
| Normalized Earnings Yield | -12.55 |